7. The composition as in one of claims 1 or 2, wherein said superantigen is selected from the group consisting of staphylococcal enterotoxins, retroviral antigens, streptococcal antigens, mycoplasma antigens, mycobacteria antigens, viral antigens and protozoan antigens.

8. The composition as in one of claims 1 or 2, wherein said superantigen comprises staphylococcal enterotoxins.

9. The composition as in one of claims 1 or 2, wherein said superantigen is selected from the group consisting of SEA, SEB, SEC_1, SEC_2, SEC_3, SED, SEE and TSST.

10. The composition as in one of claims 1 or 2, wherein said superantigen is from a virus selected from the group consisting of mouse mammary tumor virus, rabies virus and herpes virus.

11. The composition as in one of claims 1 or 2, wherein said transcription control sequences are selected from the group consisting of RSV control sequences, CMV control sequences, retroviral LTR sequences, SV-40 control sequences and β-actin control sequences.

12. The composition as in one of claims 1 or 2, wherein said therapeutic composition further comprises a pharmaceutically acceptable carrier selected from the group consisting of an aqueous physiologically balanced solution, an artificial lipid-containing substrate, a natural lipid-containing substrate, an oil, an ester, a glycol, a virus and a metal particle.

13. The composition of claim 12, wherein said pharmaceutically acceptable carrier is selected from the group consisting of liposomes, micelles, cells, and an aqueous physiologically balanced solution.

14. The composition of claim 12, wherein said pharmaceutically acceptable carrier is a liposome.

15. The composition as in one of claims 1 or 2, wherein said recombinant construct is dicistronic and comprises an IRES.

16. The composition of claim 2, wherein said recombinant construct comprising a nucleic acid sequence encoding a superantigen is selected from the group consisting of PCR_3-SEB, PCR_3-SEA, PCR_3-SEB.S, PCR_3-SEA.S and PCR_3-TSST.

17. The composition of claim 2, wherein said second recombinant construct is selected from the group consisting of PCR_3-RANTES, PCR_3-MIP1α and PCR_3-MIP1β.

18. The composition of claim 1, wherein said first nucleic acid sequence and said second nucleic acid sequence are separated by an IRES.

19. The method as in one of claims 3–6, wherein said superantigen is selected from the group consisting of staphylococcal enterotoxins, retroviral antigens, streptococcal antigens, mycoplasma antigens, mycobacteria antigens, viral antigens and protozoan antigens.

20. The method as in one of claims 3–6, wherein said transcription control sequences are selected from the group consisting of RSV control sequences, CMV control sequences, retroviral LTR sequences, SV-40 control sequences and β-actin control sequences.

21. The method as in one of claims 3–6, wherein said mammal is a human.

22. The method as in one of claims 3–6, wherein said mammal is selected from the group consisting of humans, dogs, cats, sheep, cattle, horses and pigs.

23. The method as in one of claims 3–6, wherein said cancer is selected from the group consisting of melanomas, squamous cell carcinoma, breast cancers, head and neck carcinomas, thyroid carcinomas, soft tissue sarcomas, bone sarcomas, testicular cancers, prostatic cancers, ovarian cancers, bladder cancers, skin cancers, brain cancers, angiosarcomas, hemangiosarcomas, mast cell tumors, primary hepatic cancers, lung cancers, pancreatic cancers, gastrointestinal cancers, renal cell carcinomas, and hematopoietic neoplasias.

24. The method as in one of claims 3–6, wherein said cancer is selected from the group consisting of melanomas, lung cancers, thyroid carcinomas, breast cancers, renal cell carcinomas, squamous cell carcinomas, brain tumors and skin cancers.

25. The method as in one of claims 3 or 4, wherein said liposome delivery vehicle includes a compound which specifically delivers said liposome to said cancer.

26. The method as in one of claims 3 or 4, wherein said therapeutic composition is administered to said mammal at or adjacent to said cancer.

27. The method as in one of claims 4 or 6, wherein said recombinant construct comprising a nucleic acid sequence encoding a superantigen is selected from the group consisting of PCR_3-SEB, PCR_3-SEA, PCR_3-SEB.S, PCR_3-SEA.S and PCR_3-TSST.

28. The method as in one of claims 4 or 6, wherein said second recombinant construct is selected from the group consisting of PCR_3-RANTES, PCR_3-MIP1α and PCR_3-MIP1β.

* * * * *